Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Alzheimer Disease
PharmAthene's Recombinant Butyrylcholinesterase (rBChE) May Play a Neuroprotective Role in Alzheimer's Disease
April 25th, 2008
PharmAthene, Inc. (AMEX:PIP) a biodefense company specializing in the development and commercialization of medical countermeasures against chemical and biological threats, announced that scientists from the Hebrew University of Jerusalem, one of PharmAthene's collaboration partners, have recently obtained new data suggesting that recombinant butyrylcholinesterase (rBChE), a non-pegylated form of Protexia(R), may have neuroprotective benefits. Recent research conducted by Dr. Hermona Soreq and co-workers at the Alexander Silberman Life Sciences Institute at The Hebrew University of Jerusalem, in collaboration with PharmAthene, examined the role of rBChE in the prevention...
Source: Health Business Week (2008-04-25)
|
